Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment

BACKGROUND: Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes hepatic metabolism primarily via UGT1A1; thus hepatic impairment has the potential to affect CAB exposure. METHODS: This was a multi-center, single-dose, open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaik, Jafar Sadik, Ford, Susan, Lou, Yu, Zhang, Zhiping, Bakshi, Kalpana, Tenorio, Allan, Trezza, Christine, Spreen, William, Patel, Parul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631467/
http://dx.doi.org/10.1093/ofid/ofx163.1084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631467/
http://dx.doi.org/10.1093/ofid/ofx163.1084

Ejemplares similares